| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | MRT5500, VAW00001 |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
TheSanofi–Translate Bio COVID-19 vaccine, also known asMRT5500 orVAW00001, was aCOVID-19 vaccine candidate developed bySanofi Pasteur andTranslate Bio.[3][4] The development was stopped in September 2021.[5]
In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with aUS$425 million partnership.[6]
Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such asPfizer's andModerna's) already on the market. Despite this, the company reported "promising results" in its initial trials.[5]Sanofi has continued testingits recombinant protein vaccine, developed collaboratively withGlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines.[5]
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
